Semaglutide clinical trial results explained
The STEP trials in plain language — the pivotal 14.9% result, two-year durability, regain after stopping, and how to turn efficacy into cost-per-result.
STEP 1: the trial that defined semaglutide for weight loss
Semaglutide's weight-management evidence base is the STEP program — a series of phase 3 randomized trials of the FDA-approved brand product (Wegovy). The pivotal STEP 1 trial enrolled 1,961 adults with obesity or overweight-plus-comorbidity, without diabetes, over 68 weeks. Mean weight loss was about 14.9% with semaglutide 2.4 mg versus 2.4% on placebo. The co-primary endpoint of losing at least 5% of body weight was reached by 86.4% of the semaglutide group versus 31.5% on placebo — an odds ratio around 11. Roughly a third of participants lost 20% or more, a threshold previously associated mainly with bariatric surgery.
The full STEP program
Later trials extended the picture. STEP 3 paired semaglutide with intensive behavioral therapy (~16% loss). STEP 4 studied what happens when treatment continues versus stops after a 20-week lead-in. STEP 5 followed patients for two years and found sustained mean loss of about 15.2%. STEP 8 compared semaglutide against the older GLP-1 liraglutide, and semaglutide produced substantially greater loss. The STEP 1 extension revealed the flip side: after stopping, participants regained about two-thirds of lost weight within a year — the subject of our maintenance-economics piece.
| Trial | Duration | Mean weight loss | Note |
|---|---|---|---|
| STEP 1 | 68 weeks | ~14.9% | Pivotal; no diabetes |
| STEP 2 | 68 weeks | ~9.6% | Adults with type 2 diabetes |
| STEP 3 | 68 weeks | ~16.0% | + intensive behavioral therapy |
| STEP 5 | 104 weeks | ~15.2% | Two-year sustained |
| STEP 1 extension | +52 wk off-drug | ~5.6% net | Regain after stopping |
How results differ across patient groups
The STEP program deliberately tested different populations, and results are not identical from one trial to the next — a nuance that matters when translating headline figures into personal expectations. STEP 2 studied adults who also had type 2 diabetes and found smaller average weight loss (~9.6%), reflecting a consistent pattern: people with diabetes tend to lose somewhat less. STEP 3 added intensive behavioral therapy and reached ~16%, showing structured lifestyle support meaningfully amplifies the drug effect rather than being redundant to it. Two lessons follow for a cost-conscious reader: your own comorbidities shift the expected benefit, and the program wrapped around the molecule — coaching, structured support — changes the result, not just the experience. That is the evidence behind weighting clinical support in provider selection.
Turning efficacy into cost-per-result
Efficacy becomes a buying decision when you divide by price. Using July 2026 flat-rate compounded pricing (~$145/month, ~$1,740/year) against STEP 1's ~14.9% average, the implied cost per percentage point of expected weight loss is far lower than at brand retail — though the compounded product is not FDA-approved and its real-world performance is not established by these brand trials.
| Scenario (annual) | Cost/year | Trial-avg % lost | Cost per 1% (illustrative) |
|---|---|---|---|
| Flat-rate compounded ($145/mo) | $1,740 | ~14.9% | ~$117 |
| Membership (~$230/mo) | ~$2,760 | ~14.9% | ~$185 |
| Brand Wegovy retail (~$1,349/mo) | ~$16,188 | ~14.9% | ~$1,086 |
Three honest caveats: trial averages hide wide individual variation; STEP studied the brand, so applying these percentages to a compounded product is an assumption, not a finding; and weight loss reverses substantially after stopping, so the durable comparison is annual cost of continued therapy.
Frequently asked questions
How much weight did people lose on semaglutide in trials?
In STEP 1 (68 weeks, adults with obesity without diabetes), mean weight loss was ~14.9% with semaglutide 2.4 mg versus 2.4% on placebo, and 86.4% lost at least 5% of body weight. Individual results vary; these are figures for the FDA-approved brand product.
Does semaglutide weight loss last?
In the two-year STEP 5 trial, sustained mean loss of ~15.2% was maintained with continued treatment. However, the STEP 1 extension showed that after stopping, participants regained about two-thirds of lost weight within a year.
Do compounded semaglutide products match trial results?
There's no trial base for compounded semaglutide specifically. STEP results describe the FDA-approved brand product. Compounded products are not FDA-approved and their real-world performance is not established by these trials.
What is the cost per percent of weight loss?
Dividing July 2026 annual cost by STEP 1's ~14.9% average gives roughly $117 per percentage point on a $145/mo flat plan, ~$185 on a membership model, and ~$1,086 at brand retail — an illustrative pricing comparison, not a clinical claim.
How real-world results compare to the trials
Trial averages set expectations, but the question every buyer actually has is whether those numbers hold outside a controlled study. Real-world evidence is now accumulating, and it broadly supports the trials while adding useful nuance. A large US retrospective cohort of adults on semaglutide 2.4 mg found weight loss in the mid-teens percent range at 52 to 68 weeks — close to STEP 1, though real-world adherence is lower and dropout higher, which pulls average results down for the full population that starts treatment. The gap between efficacy (how well a drug works in a trial) and effectiveness (how well it works in practice) is mostly a story about adherence: people who stay on the medication and titrate to an effective dose tend to track the trial numbers, while those who stop early for side effects, cost, or access see less. This is precisely why the wrapper around the molecule matters so much for real-world results. A program that keeps you supported through the rough titration weeks, keeps the price predictable so cost never forces an abrupt stop, and answers questions quickly is not a luxury — it is part of what determines whether you get the outcome at all. When comparing providers, the retention-supporting features are not add-ons to evaluate after price; they help determine whether you reach a trial-like result.
How real-world results compare to the trials
Trial averages set expectations, but the question every buyer actually has is whether those numbers hold outside a controlled study. Real-world evidence is now accumulating, and it broadly supports the trials while adding useful nuance. A large US retrospective cohort of adults on semaglutide 2.4 mg found weight loss in the mid-teens percent range at 52 to 68 weeks — close to STEP 1, though real-world adherence is lower and dropout higher, which pulls average results down for the full population that starts treatment. The gap between efficacy (how well a drug works in a trial) and effectiveness (how well it works in practice) is mostly a story about adherence: people who stay on the medication and titrate to an effective dose tend to track the trial numbers, while those who stop early for side effects, cost, or access see less. This is precisely why the wrapper around the molecule matters so much for real-world results. A program that keeps you supported through the rough titration weeks, keeps the price predictable so cost never forces an abrupt stop, and answers questions quickly is not a luxury — it is part of what determines whether you get the outcome at all. When comparing providers, the retention-supporting features are not add-ons to evaluate after price; they help determine whether you reach a trial-like result.
References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021.
- Garvey WT, et al. Two-year effects of semaglutide (STEP 5). Nat Med. 2022.
- Wilding JPH, et al. Weight regain after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab. 2022.
- Novo Nordisk. Wegovy (semaglutide) Prescribing Information, FDA label.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.